These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 23343427

  • 1. Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis: a prospective, multicenter, observational study (AVANTI).
    Chuchalin A, Zakharova M, Dokic D, Tokić M, Marschall HP, Petri T.
    BMC Pulm Med; 2013 Jan 23; 13():5. PubMed ID: 23343427
    [Abstract] [Full Text] [Related]

  • 2. Characterisation of exacerbations of chronic bronchitis and COPD in Europe: the GIANT study.
    Miravitlles M, Anzueto A, Ewig S, Legnani D, Stauch K.
    Ther Adv Respir Dis; 2009 Dec 23; 3(6):267-77. PubMed ID: 19880426
    [Abstract] [Full Text] [Related]

  • 3. Identifying patients at risk of late recovery (≥ 8 days) from acute exacerbation of chronic bronchitis and COPD.
    Anzueto A, Miravitlles M, Ewig S, Legnani D, Heldner S, Stauch K.
    Respir Med; 2012 Sep 23; 106(9):1258-67. PubMed ID: 22749710
    [Abstract] [Full Text] [Related]

  • 4. A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodology.
    Wilson R, Anzueto A, Miravitlles M, Arvis P, Faragó G, Haverstock D, Trajanovic M, Sethi S.
    Int J Chron Obstruct Pulmon Dis; 2011 Sep 23; 6():373-83. PubMed ID: 21760724
    [Abstract] [Full Text] [Related]

  • 5. Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD.
    Miravitlles M.
    Int J Chron Obstruct Pulmon Dis; 2007 Sep 23; 2(3):191-204. PubMed ID: 18229559
    [Abstract] [Full Text] [Related]

  • 6. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis.
    Starakis I, Gogos CA, Bassaris H.
    Int J Antimicrob Agents; 2004 Feb 23; 23(2):129-37. PubMed ID: 15013037
    [Abstract] [Full Text] [Related]

  • 7. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis.
    DeAbate CA, Mathew CP, Warner JH, Heyd A, Church D.
    Respir Med; 2000 Nov 23; 94(11):1029-37. PubMed ID: 11127487
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results.
    Wilson R, Anzueto A, Miravitlles M, Arvis P, Alder J, Haverstock D, Trajanovic M, Sethi S.
    Eur Respir J; 2012 Jul 23; 40(1):17-27. PubMed ID: 22135277
    [Abstract] [Full Text] [Related]

  • 10. Real-life treatment of acute exacerbations of chronic bronchitis with moxifloxacin or macrolides: a comparative post-marketing surveillance study in general practice.
    Schaberg T, Möller M, File T, Stauch K, Landen H.
    Clin Drug Investig; 2006 Jul 23; 26(12):733-44. PubMed ID: 17274680
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI).
    Kuzman I, Bezlepko A, Kondova Topuzovska I, Rókusz L, Iudina L, Marschall HP, Petri T.
    BMC Pulm Med; 2014 Jun 30; 14():105. PubMed ID: 24975809
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis.
    Zervos M, Martinez FJ, Amsden GW, Rothermel CD, Treadway G.
    Int J Antimicrob Agents; 2007 Jan 30; 29(1):56-61. PubMed ID: 17189096
    [Abstract] [Full Text] [Related]

  • 13. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.
    Sethi S, Jones PW, Theron MS, Miravitlles M, Rubinstein E, Wedzicha JA, Wilson R, PULSE Study group.
    Respir Res; 2010 Jan 28; 11(1):10. PubMed ID: 20109213
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis.
    Pea F, Pavan F, Lugatti E, Dolcet F, Talmassons G, Screm MC, Furlanut M.
    Clin Pharmacokinet; 2006 Jan 28; 45(3):287-95. PubMed ID: 16509760
    [Abstract] [Full Text] [Related]

  • 16. The role of topical moxifloxacin, a new antibacterial in Europe, in the treatment of bacterial conjunctivitis.
    Benitez-Del-Castillo J, Verboven Y, Stroman D, Kodjikian L.
    Clin Drug Investig; 2011 Jan 28; 31(8):543-557. PubMed ID: 21604820
    [Abstract] [Full Text] [Related]

  • 17. [Moxifloxacin in the treatment of chronic bronchitis--clinical evaluation and assessment by patients].
    Lorenz J, Busch W, Thate-Waschke IM, Bronchimox--Studiengruppe.
    Fortschr Med Orig; 2000 Jul 27; 118 Suppl 2():63-70. PubMed ID: 15700488
    [Abstract] [Full Text] [Related]

  • 18. Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort.
    Urueta-Robledo J, Ariza H, Jardim JR, Caballero A, García-Calderón A, Amábile-Cuevas CF, Hernández-Oliva G, Vivar-Orozco R, MOX-CB Study Group.
    Respir Med; 2006 Sep 27; 100(9):1504-11. PubMed ID: 16504492
    [Abstract] [Full Text] [Related]

  • 19. A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis.
    Schaberg T, Ballin I, Huchon G, Bassaris H, Hampel B, Reimnitz P, AECB Study Group.
    J Int Med Res; 2001 Sep 27; 29(4):314-28. PubMed ID: 11675905
    [Abstract] [Full Text] [Related]

  • 20. The diagnosis and treatment of elderly patients with acute exacerbation of chronic obstructive pulmonary disease and chronic bronchitis.
    Albertson TE, Louie S, Chan AL.
    J Am Geriatr Soc; 2010 Mar 27; 58(3):570-9. PubMed ID: 20398122
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.